专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20160243103A1 Treatment of BDNF-Related Disorders Using Laquinimod 审中-公开
标题翻译：使用Laquinimod治疗BDNF相关性疾病
公开(公告)号：US20160243103A1
公开(公告)日：2016-08-25
申请号：US15049942
申请日：2016-02-22
申请人： Liat Hayardeny
发明人： Liat Hayardeny
IPC分类号： A61K31/4704 , A61K9/00
CPC分类号： A61K31/4704 , A61K9/0053 , A61K9/20 , A61K31/138 , A61K31/428 , A61K2300/00
摘要： This application provides for a method of increasing brain-derived neurotrophic factor (BDNF) serum level in a human subject comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to increase BDNF serum level in the human subject. The method can further comprise periodically administering to the subject an amount of a second BDNF-increasing agent. This application also provides for a method for treating a human subject suffering from a BDNF-related disease comprising periodically administering laquinimod or a pharmaceutically acceptable salt thereof in an amount effective to treat the human subject. This application additionally provides for use of laquinimod in the manufacture of a medicament for increasing BDNF serum, level in a human subject. This application further provides for a pharmaceutical composition comprising an amount of laquinimod effective for use in increasing BDNF serum level in a human subject. This application also provides for a pharmaceutical preparation comprising an amount of laquinimod and an amount of a second BDNF-increasing agent effective for use in increasing BDNF serum level in a human subject.
摘要翻译：本申请提供了增加人受试者脑源性神经营养因子（BDNF）血清水平的方法，其包括向受试者定期施用一定量的有效增加人受试者BDNF血清水平的拉喹莫德或其药学上可接受的盐。该方法可以进一步包括向受试者周期性施用一定量的第二BDNF增加剂。本申请还提供了治疗患有BDNF相关疾病的人受试者的方法，其包括以有效治疗人受试者的量定期施用拉喹莫德或其药学上可接受的盐。本申请另外提供了用于制备用于增加BDNF血清，人类受试者水平的药物中的拉喹莫德的用途。本申请还提供了一种药物组合物，其包含一定量的用于增加人受试者中BDNF血清水平的有效成分的拉喹莫德。本申请还提供了一种药物制剂，其包含一定量的拉喹莫德和一定量的有效用于增加人类受试者中BDNF血清水平的第二BDNF增加剂。

12. 发明申请

US20140271532A1 COMBINATION THERAPY WITH GLATIRAMER ACETATE AND RASAGILINE FOR THE TREATMENT OF MULTIPLE SCLEROSIS 审中-公开
标题翻译：用于治疗多发性硬化症的乙酰胆碱酯酶和RASAGILINE的联合治疗
公开(公告)号：US20140271532A1
公开(公告)日：2014-09-18
申请号：US14292511
申请日：2014-05-30
申请人： Rivka Kreitman , Liat Hayardeny , Eran Blaugrund , Ruth Levy
发明人： Rivka Kreitman , Liat Hayardeny , Eran Blaugrund , Ruth Levy
IPC分类号： A61K31/78 , A61K31/137
CPC分类号： A61K31/78 , A61K31/135 , A61K31/137 , A61K31/785 , A61K38/02 , A61K45/06 , A61K2300/00
摘要： The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, rasagiline or the pharmaceutically acceptable salt thereof and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject.
摘要翻译：本发明提供了治疗患有多发性硬化症形式的受试者的方法，其包括向受试者定期施用一定量的醋酸格拉司定和一定量的雷沙吉兰或其药学上可接受的盐，其中一起使用的量有效缓解在受试者中多发性硬化形式的症状，从而治疗受试者。本发明还提供了一种包含醋酸格拉默，雷沙吉兰或其药学上可接受的盐的包装，以及用于一起减轻受试者中多发性硬化症状的症状的说明书。本发明进一步提供药物组合，其包含一定量的醋酸格拉司定的单独剂量形式和一定量的雷沙吉兰或其药学上可接受的盐，该组合可用于减轻受试者中多发性硬化形式的症状。

13. 发明申请

US20120027718A1 COMBINATION THERAPY WITH GLATIRAMER ACETATE AND RASAGILINE FOR THE TREATMENT OF MULTIPLE SCLEROSIS 审中-公开
标题翻译：用于治疗多发性硬化症的乙酰胆碱酯酶和RASAGILINE的联合治疗
公开(公告)号：US20120027718A1
公开(公告)日：2012-02-02
申请号：US13198229
申请日：2011-08-04
申请人： Rivka Kreitman , Liat Hayardeny , Ruth Levy , Eran Blaugrund
发明人： Rivka Kreitman , Liat Hayardeny , Ruth Levy , Eran Blaugrund
IPC分类号： A61K31/785 , A61P37/02 , A61P25/00
CPC分类号： A61K31/78 , A61K31/135 , A61K31/137 , A61K31/785 , A61K38/02 , A61K45/06 , A61K2300/00
摘要： The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, rasagiline or the pharmaceutically acceptable salt thereof and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject.
摘要翻译：本发明提供了治疗患有多发性硬化症形式的受试者的方法，其包括向受试者定期施用一定量的醋酸格拉司定和一定量的雷沙吉兰或其药学上可接受的盐，其中一起使用的量有效缓解在受试者中多发性硬化形式的症状，从而治疗受试者。本发明还提供了一种包含醋酸格拉默，雷沙吉兰或其药学上可接受的盐的包装，以及用于一起减轻受试者中多发性硬化症状的症状的说明书。本发明进一步提供药物组合，其包含一定量的醋酸格拉司定的单独剂量形式和一定量的雷沙吉兰或其药学上可接受的盐，该组合可用于减轻受试者中多发性硬化形式的症状。

14. 发明申请

US20180064702A1 TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS WITH LAQUINIMOD 审中-公开
公开(公告)号：US20180064702A1
公开(公告)日：2018-03-08
申请号：US15811139
申请日：2017-11-13
申请人： Nora Tarcic , Dan Bar-Zohar , Liat Hayardeny , Yossi Gilgun Sherki , Tali Gorfine , Volker Knappertz , Ella Sorani
发明人： Nora Tarcic , Dan Bar-Zohar , Liat Hayardeny , Yossi Gilgun Sherki , Tali Gorfine , Volker Knappertz , Ella Sorani
IPC分类号： A61K31/4704
CPC分类号： A61K31/4704
摘要： This invention provides a method for treating a human subject afflicted with a progressive form of multiple sclerosis, comprising periodically administering to the human subject an amount of laquinimod effective to treat the human subject. This invention also provides laquinimod for use in treating a human subject afflicted with a progressive form of multiple sclerosis. This invention further provides pharmaceutical compositions and packages comprising an effective amount of laquinimod for treating a progressive form of multiple sclerosis.

15. 发明申请

US20110034508A1 Treatment of BDNF-related disorders using laquinimod 有权
标题翻译：使用拉喹莫德治疗BDNF相关疾病
公开(公告)号：US20110034508A1
公开(公告)日：2011-02-10
申请号：US12806275
申请日：2010-08-09
申请人： Liat Hayardeny
发明人： Liat Hayardeny
IPC分类号： A61K31/4704 , A61P25/00
CPC分类号： A61K31/4704 , A61K9/0053 , A61K9/20 , A61K31/138 , A61K31/428 , A61K2300/00
摘要： This application provides for a method of increasing brain-derived neurotrophic factor (BDNF) serum level in a human subject comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to increase BDNF serum level in the human subject. The method can further comprise periodically administering to the subject an amount of a second BDNF-increasing agent. This application also provides for a method for treating a human subject suffering from a BDNF-related disease comprising periodically administering laquinimod or a pharmaceutically acceptable salt thereof in an amount effective to treat the human subject. This application additionally provides for use of laquinimod in the manufacture of a medicament for increasing BDNF serum level in a human subject. This application further provides for a pharmaceutical composition comprising an amount of laquinimod effective for use in increasing BDNF serum level in a human subject. This application also provides for a pharmaceutical preparation comprising an amount of laquinimod and an amount of a second BDNF-increasing agent effective for use in increasing BDNF serum level in a human subject.
摘要翻译：本申请提供了增加人受试者脑源性神经营养因子（BDNF）血清水平的方法，其包括向受试者定期施用一定量的有效增加人受试者BDNF血清水平的拉喹莫德或其药学上可接受的盐。该方法可以进一步包括向受试者周期性施用一定量的第二BDNF增加剂。本申请还提供了治疗患有BDNF相关疾病的人受试者的方法，其包括以有效治疗人受试者的量定期施用拉喹莫德或其药学上可接受的盐。本申请另外提供了在制备用于增加人受试者中BDNF血清水平的药物中的用途。本申请还提供了一种药物组合物，其包含一定量的用于增加人受试者中BDNF血清水平的有效成分的拉喹莫德。本申请还提供了一种药物制剂，其包含一定量的拉喹莫德和一定量的有效用于增加人类受试者中BDNF血清水平的第二BDNF增加剂。

16. 发明申请

US20170239234A1 TREATMENT OF BDNF-RELATED DISORDERS USING LAQUINIMOD 审中-公开
公开(公告)号：US20170239234A1
公开(公告)日：2017-08-24
申请号：US15426626
申请日：2017-02-07
申请人： Liat Hayardeny
发明人： Liat Hayardeny
IPC分类号： A61K31/4704 , A61K9/20 , A61K9/00
CPC分类号： A61K31/4704 , A61K9/0053 , A61K9/20 , A61K31/138 , A61K31/428 , A61K2300/00
摘要： This application provides for a method of increasing brain-derived neurotrophic factor (BDNF) serum level in a human subject comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to increase BDNF serum level in the human subject. The method can further comprise periodically administering to the subject an amount of a second BDNF-increasing agent. This application also provides for a method for treating a human subject suffering from a BDNF-related disease comprising periodically administering laquinimod or a pharmaceutically acceptable salt thereof in an amount effective to treat the human subject. This application additionally provides for use of laquinimod in the manufacture of a medicament for increasing BDNF serum level in a human subject. This application further provides for a pharmaceutical composition comprising an amount of laquinimod effective for use in increasing BDNF serum level in a human subject. This application also provides for a pharmaceutical preparation comprising an amount of laquinimod and an amount of a second BDNF-increasing agent effective for use in increasing BDNF serum level in a human subject.

17. 发明申请

US20100167983A1 Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis 审中-公开
标题翻译：用醋酸格拉默和雷沙吉兰联合治疗多发性硬化症
公开(公告)号：US20100167983A1
公开(公告)日：2010-07-01
申请号：US12660581
申请日：2010-03-01
申请人： Rivka Kreitman , Liat Hayardeny , Ruth Levy , Eran Blaugrund
发明人： Rivka Kreitman , Liat Hayardeny , Ruth Levy , Eran Blaugrund
IPC分类号： A61K38/00 , A61P25/28
CPC分类号： A61K31/78 , A61K31/135 , A61K31/137 , A61K31/785 , A61K38/02 , A61K45/06 , A61K2300/00
摘要： The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, rasagiline or the pharmaceutically acceptable salt thereof and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject.
摘要翻译：本发明提供了治疗患有多发性硬化症形式的受试者的方法，其包括向受试者定期施用一定量的醋酸格拉司定和一定量的雷沙吉兰或其药学上可接受的盐，其中一起使用的量有效缓解在受试者中多发性硬化形式的症状，从而治疗受试者。本发明还提供了一种包含醋酸格拉默，雷沙吉兰或其药学上可接受的盐的包装，以及用于一起减轻受试者中多发性硬化症状的症状的说明书。本发明进一步提供药物组合，其包含一定量的醋酸格拉司定的单独剂量形式和一定量的雷沙吉兰或其药学上可接受的盐，该组合可用于减轻受试者中多发性硬化形式的症状。

18. 发明申请

US20080261894A1 Combination Therapy with Glatiramer Acetate and Rasagiline for the Treatment of Multiple Sclerosis 审中-公开
标题翻译：联合治疗醋酸格拉美和雷沙吉兰治疗多发性硬化症
公开(公告)号：US20080261894A1
公开(公告)日：2008-10-23
申请号：US11884633
申请日：2006-02-17
申请人： Rivka Kreitman , Liat Hayardeny , Ruth Levy , Eran Blaugrund
发明人： Rivka Kreitman , Liat Hayardeny , Ruth Levy , Eran Blaugrund
IPC分类号： A61K38/07
CPC分类号： A61K31/135 , A61K38/02 , A61K2300/00
摘要： The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, rasagiline or the pharmaceutically acceptable salt thereof and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject.
摘要翻译：本发明提供了治疗患有多发性硬化症形式的受试者的方法，其包括向受试者定期施用一定量的醋酸格拉司定和一定量的雷沙吉兰或其药学上可接受的盐，其中一起使用的量有效缓解在受试者中多发性硬化形式的症状，从而治疗受试者。本发明还提供了一种包含醋酸格拉默，雷沙吉兰或其药学上可接受的盐的包装，以及用于一起减轻受试者中多发性硬化症状的症状的说明书。本发明进一步提供药物组合，其包含一定量的醋酸格拉司定的单独剂量形式和一定量的雷沙吉兰或其药学上可接受的盐，该组合可用于减轻受试者中多发性硬化形式的症状。

19. 发明申请

US20070037740A1 Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis 审中-公开
标题翻译：联合治疗醋酸格拉默和阿尔卡必利醇治疗多发性硬化症
公开(公告)号：US20070037740A1
公开(公告)日：2007-02-15
申请号：US10547463
申请日：2004-03-04
申请人： Irit Pinchasi , Dina Kofler , Liat Hayardeny
发明人： Irit Pinchasi , Dina Kofler , Liat Hayardeny
IPC分类号： A61K38/16 , A61K31/59
CPC分类号： A61K45/06 , A61K31/59 , A61K38/02 , A61K2300/00
摘要： The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of alphacalcidol, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, alphacalcidol and instructions for use of them together to alleviate a symptom of a form of multiple sclerosis in a subject. Additionally, the subject invention provides a pharmaceutical composition comprising an amount of glatiramer acetate and an amount of alphacalcidol, wherein the amounts when taken together are effective to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of alphacalcidol, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject.
摘要翻译：本发明提供了一种治疗患有多发性硬化症形式的受试者的方法，其包括向受试者定期施用一定量的醋酸格拉司定和一定量的阿尔卡可骨醇，其中一起使用的量可有效减轻以下形式的症状：多发性硬化症，从而治疗受试者。本发明还提供了一种包含乙酸格拉默酮，阿卡非尔多醇和它们一起用于减轻受试者中多发性硬化形式的症状的说明书。另外，本发明提供一种包含一定量的醋酸格拉默和一定量的角化石烷醇的药物组合物，其中一起使用的量可有效减轻受试者中多发性硬化形式的症状。本发明进一步提供药物组合，其包含单独的剂量形式的一定量的醋酸格拉司亭和一定量的阿尔卡可醇，该组合可用于缓解受试者中多发性硬化形式的症状。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式